



## Case Report

Hyperphosphatasia with mental retardation syndrome, expanded phenotype of *PIGL* related disordersRuqaiyah Altassan<sup>a</sup>, Stephanie Fox<sup>a</sup>, Chantal Poulin<sup>b</sup>, Daniela Buhas<sup>a,c,\*</sup><sup>a</sup> Department of Medical Genetics, Montreal Children's Hospital, McGill University Health Center, Montreal, Quebec, Canada<sup>b</sup> Department of Pediatric, Division of Neurology, Montreal Children's Hospital, McGill University Health Center, Montreal, Quebec, Canada<sup>c</sup> Department of Human Genetics, McGill University, Montreal, Quebec, Canada

## ARTICLE INFO

## Keywords:

GPI biogenesis  
Hyperphosphatasia mental retardation syndrome (HPMRS)  
Mabry syndrome  
*PIGL* gene  
CHIME syndrome

## ABSTRACT

Hypomorphic mutations in six different genes involved in the glycosylphosphatidylinositol (GPI) biogenesis pathway are linked to Mabry syndrome (hyperphosphatasia with mental retardation syndrome, HPMRS). This report on the third affected family with a HPMRS phenotype caused by mutations in *PIGL*, confirming the seventh GPI biogenesis gene linked to HPMRS. Two siblings presented with the main features of HPMRS; developmental delay, cognitive impairment, seizure disorder, skeletal deformities, and high alkaline phosphatase. We identified two heterozygous mutations in the *PIGL* gene (P.Trp20Ter and p.Arg88Cys). *PIGL* mutations have been linked to another distinctive neuroectodermal disorder: CHIME syndrome. The clinical picture of our patients expands the spectrum of *PIGL*-related phenotypes.

## 1. Introduction

Glycosylphosphatidylinositol (GPI) glycolipids play a critical role in the post-translation modification and cell membrane anchoring of > 150 eukaryotic proteins which ultimately affect the sorting, trafficking, and dynamics of those proteins. Also, they participate in the process of embryogenesis, neurogenesis, immune responses, and fertilization. The biogenesis of mature GPI involves > 20 genes and occurs in eukaryotes via a conserved post-translational pathway [1].

In animal studies, complete deletion of the GPI pathway results in embryonic lethality. However, complete deletion has not been reported in humans. Hypomorphic mutations in the genes encoding the GPI biogenesis pathway result in partial reduction of GPI-anchored proteins, which leads to phenotypically heterogeneous clinical presentations, with global developmental delay a common feature. This element supports the notion that GPI-anchored proteins play a vital role in neurogenesis [2,3].

*PIGL* encodes the endoplasmic phosphatidylinositol glycan anchor biosynthesis class L, which is involved in the second step of GPI biosynthesis: the de-n-acetylation of n-acetylglucosaminyl-phosphatidylinositol (GluNAc-PI), generating glucosaminyl-phosphatidylinositol (GlcN-PI) on the cytoplasmic side of the endoplasmic reticulum [4].

Mutations in *PIGL* have been linked to two rare distinctive

syndromes: CHIME syndrome (Zunich neuroectodermal syndrome) and Mabry syndrome (hyperphosphatasia with mental retardation syndrome, HPMRS) [5,6].

## 2. Clinical data

The proband is a 10-year-old West African male who is the first offspring of a non-consanguineous couple. He was delivered spontaneously at term after an uneventful pregnancy weighing 2665 g (5th percentile) with a head circumference of 32 cm (5th percentile) and Apgar score of 9. At the age of 6 months, he presented with myoclonic seizures that were partially controlled with medications. By the age of 12 months, he had surgical correction of inguinal hernia, hydrocele, and strabismus. His developmental milestones were globally delayed, including cognitive, language, gross and fine motor functions, with no major improvement despite intensive rehabilitation. His first available baseline physical examination was documented at 4 years of age. Growth parameters were normal with weight, height and head circumference on the 75th percentile. The facial features were coarsely dysmorphic, including prominent forehead, high arched eyebrows and sparse on the outer third, nystagmus, mild telecanthus, uplifted ear lobes, and open mouth with intermittent drooling. In addition, he had mild pectus excavatum and clinodactyly involving the fifth digits, 4th

**Abbreviations:** GPI, glycosylphosphatidylinositol; HPMRS, hyperphosphatasia with mental retardation syndrome; CHIME, ocular colobomas, heart defect, ichthyosis, mental retardation, and abnormal ears or epilepsy; *PIGL*, phosphatidylinositol glycan anchor biosynthesis class L; ALP, alkaline phosphatase; CSS, Coffin-Siris syndrome

\* Corresponding author at: Department of Medical Genetics, Montreal Children's Hospital, McGill University Health Center, 1001 Decarie Boulevard, Montreal, Quebec QC H4A 3J1, Canada.

E-mail address: [Daniela.buhas@mcgill.ca](mailto:Daniela.buhas@mcgill.ca) (D. Buhas).

<https://doi.org/10.1016/j.ymgmr.2018.01.007>

Received 8 December 2017; Received in revised form 26 January 2018; Accepted 26 January 2018

2214-4269/© 2018 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1. X-ray hands showed deformity of the middle phalanx of the 5th finger bilaterally with the lateral aspect of the phalanx being shorter than the medial aspect.

and 5th toes bilaterally. (Fig. 1, hand X-ray). No skin abnormalities were noted. Other features included reducible umbilical hernia, mild hepatomegaly, and ataxic gait. Audiology and heart evaluations were normal. Brain MRI showed symmetrical bilateral patchy signal abnormalities in the periventricular zones in the parietal, occipital and frontal regions, white matter loss, and thin corpus callosum. Liver enzymes showed mildly elevated transaminases with significantly elevated ALP 968 U/L (normal: 135–320 U/L). Vitamin E and alpha-feto-protein were normal. All metabolic tests were unremarkable, including but not limited to purines/pyrimidines, glycosaminoglycans, creatine panel, carbohydrate transferrin, homocysteine, sterol profiles, and creatine kinase. Array CGH and Coffin-Siris molecular testing were normal.

Evaluation of the patient's younger 4-year-old brother revealed a very similar presentation. He had unremarkable antenatal and perinatal history. His developmental milestones were globally delayed. He developed his first onset of partially controlled tonic-clonic seizures at the age of 4 months. Strabismus was surgically corrected at the age of 1 year. On examination, he was inattentive with coarse facial features including high hairlines, hypertelorism, epicanthal folds, horizontal nystagmus, depressed nasal bridge, delayed teeth eruption, everted and partially bifid lower lip, folded ears, and irregular hypopigmented skin margins surrounding the eyes and the nose. His head circumference was 51 cm (75th percentile). Systemic examination revealed spastic lower limbs, bilateral brachydactyly, severe clinodactyly of both fifth fingers and toes and dry eczematous skin. No chest deformity or organomegaly was noted. His ALP was 454 U/L.

### 3. Molecular data

A commercially available multigene panel for intellectual disability (GeneDx) was performed in the proband and revealed two variants in *PIGL* gene, a nonsense (c.60G > A; p.Trp20Ter; W20X) pathogenic variant and missense (c.262C > T; p.Arg88Cys; R88C) variant. Neither variant was observed in approximately 65,000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project. The first variant was interpreted as pathogenic as it causes loss of normal protein function through truncation or nonsense-mediated mRNA decay. For the second variant, in silico analysis predicted it as likely damaging the protein structure and function. Parental analyses

were done by Sanger sequencing and confirmed *in trans* mutations. Targeted genetic testing for the brother detected the same variants.

### 4. Discussion

In 1970, Mabry et al. described a unique syndrome comprised of severe cognitive impairment, seizures, various neurologic deficits, and elevated serum ALP [6]. This syndrome was acronymed HPMRS-1 (OMIM: 239300) [7] and linked to mutations in the *PIGV* gene, which is involved in the early steps of GPI anchor assembly [8]. Subsequently, other pathogenic defects in genes involved in either GPI anchor assembly or maturation were linked to the same phenotype. [Table 1].

The *PIGL* gene is responsible for the second step of GPI biosynthesis. Mutations in this gene were initially reported in seven cases presenting with CHIME syndrome. CHIME (OMIM: 280000, ocular Colobomas, Heart defect, Ichthyosis, Mental Retardation, and abnormal Ears or Epilepsy) was first described clinically by Zunich et al. in 1983, acronymed by Shashi et al. in 1995, and linked to *PIGL* mutations by Ng et al. in 2012. All patients presented the main features of CHIME syndrome plus a variable combination of facial dysmorphism such as brachycephaly, flat and broad nasal root, short philtrum, hypertelorism, cloudy corneas, overfolded helices, wide mouth, full lips, cleft palate, and abnormal dentation. Mildly elevated alkaline phosphatase was reported in only one patient who presented with a clinical phenotype of CHIME syndrome (not molecularly confirmed) in the setting of acute lymphocytic leukemia [5,9–12].

Recently, in addition to its association with CHIME syndrome, mutations in *PIGL* have been linked to HPMRS in two cases [13,14]. We are reporting the third family with a HPMRS phenotype secondary to *PIGL* mutations supported by the clinical presentations of cognitive delay, seizures, skeletal deformities, and elevated ALP. Our patients had some overlapping features between CHIME and HPMRS, particularly in the characteristic facial features, seizures, and global developmental delay. However, the absence of coloboma, heart defect and hearing impairment, in addition to the distinctive skeletal phenotype of short terminal phalanges and the high ALP made the presentation more suggestive of HPMRS.

The phenotypic difference between HPMRS and CHIME syndromes could be related to the type of *PIGL* mutation. All the reported cases with a HPMRS phenotype, including our patients, presented at least one

**Table 1**  
The clinical feature of the previously reported patients with Hyperphosphatasia with Mental Retardation syndrome types (HPMRS).

Type	HPMRS1	HPMRS2	HPMRS3	HPMRS4	HPMRS5	HPMRS6	HPMRS7*
Gene	PIGV	PIGO	PGAP2	PGAP3	PIGW	PIGY	PIGL
No. of reported cases	29	3	13	5	1	4	4(2 in this report)
Cognitive impairment	+	+	+	+	+	+	+
Seizure	+	+	+	+	+	+	+
High ALP	+	+	+	+	+	+	+
Growth	NA	Poor growth	NA	Poor growth	NA	Poor growth	Normal
Dysmorphic features	+	+	NA	+	+	+	+
Heart defects	VSD	ASD	NA	NA	NA	NA	No
GI/GU anomalies	Feeding problem	Anal stenosis/atresia vesicoureteral reflux	NA	NA	NA	NA	Hepatomegaly mild elevated transaminases
Brian, skull anomalies	Plagiocephaly	Microcephaly enlarged ventricles plagiocephaly coronal synostosis	Micro-cephaly cerebral atrophy	Micro-cephaly	NA	Microcephaly	Thin corpus callosum
Skeletal anomalies	Hypoplastic terminal phalanges tapered fingers hypoplastic toes bilateral adducted forefoot hypoplastic/curved nails	Brachy-telephalangy broad halluces hypoplastic/absent nails	NA	NA	NA	Joint contractures osteopenia proximal limb shortening clinodactyly	Bilateral brachydactyly severe clinodactyly of fifth fingers bilateral clinodactyly (4th and 5th toes)

Abbreviations: \*the proposed 7th type of HPMRS in this report, MR: Mental retardation, ALP: alkaline phosphatase, NA: not available, GI/GU: gastrointestinal and genitourinary systems.

*PIGL* mutation leading to complete loss of the protein's function [13,14]. On the other hand, all reported cases of CHIME shared the same p.Leu176Pro mutation in a compound heterozygous state with another pathogenic variant. Homozygous p.Leu176Pro mutations have never been reported. The p.Leu176Pro alteration has been shown to preserve some of the protein's function, thus allowing a milder phenotype [10,12].

The craniofacial features that our patients share with the first reported case of HPMRS secondary to *PIGL* mutation include hypertelorism, high palate, strabismus, ear anomalies, and the skeletal deformities of the hands. However, the additional minor facial traits described by Fujiwara et al. were lacking in our patients [13]. Interestingly, the coarse facial features observed in our patients were previously reported in patients with HPMRS where there was initial suspicion of a lysosomal storage disorder [7]. All of the HPMRS types share the phenotype of global developmental delay, seizure disorder, and high ALP [15]. The hypoplastic terminal phalanges were reported in HPMRS type 1 and 2 only. This skeletal finding could lead to suspicion of Coffin-Siris syndrome given the neurological findings in both syndromes [Table 1] [16–28].

The elevated ALP in HPMRS is the nonspecific ALPL isoform (liver/bone/kidney). Defects in GPI biogenesis affect the expression of the anchored proteins, including ALP. The exact mechanism of ALP elevation in HPMRS is not well-explained. Experimental studies on mutant CHO cells showed that defects in the genes involved in the later steps of the pathway efficiently secrete ALP into the medium and consequently give high ALP levels. In comparison, mutations in the early steps will degrade the ALP in the cells and result in normal ALP levels. Additionally, GPI transamidase, which is activated through binding with a mannose-containing GPI intermediate before the enzyme complex processes the precursor proteins for release, plays a major role in expressing the proteins [29]. This could explain the elevated ALP levels in mutations involved in some of the late steps of GPI anchor synthesis including *PIGV* (fifth step) and *PIGO* (eighth step). However, elevated ALP levels were not observed in other late steps of GPI synthesis including *PIGN* in the sixth step and *PIGT* in the tenth step. On the other hand, mutations in the final step of GPI-anchor fatty acid remodeling, mainly in *PGAP2* and *PGAP3*, resulted in an elevated ALP level [30]. Mutation in *PIGL*, which involves the second step of GPI synthesis, is another exception for the hypothesized theory. Further studies are needed to understand the factors affecting the expression of GPI-anchored proteins.

ALP is essential for dephosphorylation of the circulating pyridoxal 5-phosphate to pyridoxal. Defects in anchoring ALP could predispose to B6-responsive seizures in HPMRS in a similar manner as in hypophosphatasia (OMIM: 241500) secondary to *ALPL* (alkaline phosphatase, liver/bone/kidney) mutations as both might affect the function of the ALP enzyme. Pyridoxine supplements in two patients with HPMRS, one with *PIGO* mutations and one with unknown underlying gene mutations, showed a good clinical and electroencephalographic response [31,32].

Most of the GPI biogenesis syndromes are diagnosed by whole exome/genome sequencing due to the rarity of those disorders, the heterogeneity in the clinical phenotypes, and the lack of clear biochemical markers. Even if very rare (< 0.5% of developmental disorders), including ALP as a simple, sensitive screening test in patients presenting with unexplained developmental delay would allow detecting this sub-type of GPI biogenesis disorders [14]. Further studies are emerging to correlate elevated ALP to GPI biogenesis disorders and to potential therapies for those disorders i.e. the role of pyridoxine for seizure control.

In conclusion, our clinical, biochemical and molecular findings support the previous reports of HPMRS caused by *PIGL* mutations. *PIGL* should be considered in the differential diagnosis of the known *PIG* classes (*PIGV*, *PIGO*, and *PIGW*) and the post-GPI attachment to proteins genes (*PGAP2*, *PGAP3*) that are currently linked to HPMRS.

## Acknowledgment

We thank Dr. Sara Aldekhyl and Andrea Secord for their help in editing the manuscript, and we thank the patients' family who kindly agreed for sharing their children's cases.

## Conflict of interest

Ruqaiah Altassan declares no conflict of interest.  
 Stephanie Fox declares no conflict of interest.  
 Chantal Poulin declares no conflict of interest.  
 Daniela Buhas declares no conflict of interest.

## References

- [1] M.A.J. Ferguson, T. Kinoshita, G.W. Hart, Glycosylphosphatidylinositol anchors, in: A. Varki, R.D. Cummings, J.D. Esko, et al. (Eds.), *Essentials of Glycobiology*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY), 2009, Chapter 11. (Available from:) <https://www.ncbi.nlm.nih.gov/books/NBK1966/>.
- [2] T. Kinoshita, Biosynthesis and deficiencies of glycosylphosphatidylinositol, *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 90 (4) (2014) 130–143.
- [3] H.H. Freeze, J.X. Chong, M.J. Bamshad, B.G. Ng, Solving glycosylation disorders: fundamental approaches reveal complicated pathways, *Am. J. Hum. Genet.* 94 (2) (2014 Feb 6) 161–175.
- [4] OMIM (Online Mendelian Inheritance in Man).
- [5] J. Zunich, C.I. Kaye, New syndrome of congenital ichthyosis with neurologic abnormalities, *Am. J. Med. Genet.* 15 (2) (1983 Jun) 331–333.
- [6] C.C. Mabry, A. Bautista, R.F.H. Kirk, L.D. Dubilier, H. Braunstein, J.A. Koepke, Familial hyper phosphatase with mental retardation, seizures, and neurologic deficits, *J. Pediatr.* 77 (1) (1970 Jul) 74–85.
- [7] M.D. Thompson, M.M. Nezarati, G. Gillessen-Kaesbach, P. Meinecke, R. Mendoza-Londono, E. Mornet, I. Brun-Heath, C.P. Squarioni, L. Legeai-Mallet, A. Munnich, D.E. Cole, Hyperphosphatasia with seizures, neurologic deficit, and characteristic facial features: five new patients with Mabry syndrome, *Am. J. Med. Genet. A* 152A (7) (2010 Jul) 1661–1669.
- [8] P.M. Krawitz, M.R. Schweiger, C. Rödelberger, C. Marcellis, U. Kölsch, C. Meisel, F. Stephani, T. Kinoshita, Y. Murakami, S. Bauer, M. Isau, A. Fischer, A. Dahl, M. Kerick, J. Hecht, S. Köhler, M. Jäger, J. Grünhagen, B.J. de Condor, S. Doelken, H.G. Brunner, P. Meinecke, E. Passarge, M.D. Thompson, D.E. Cole, D. Horn, T. Roscioli, S. Mundlos, P.N. Robinson, Identity-by-descent filtering of exome sequence data identifies PIGV mutations in hyperphosphatasia mental retardation syndrome, *Nat. Genet.* 42 (10) (2010 Oct) 827–829.
- [9] V. Shashi, J. Zunich, T.E. Kelly, J.S. Fryburg, Neuroectodermal (CHIME) syndrome: an additional case with long term follow up of all reported cases, *J. Med. Genet.* 32 (6) (1995 Jun) 465–469.
- [10] B.G. Ng, K. Hackmann, M.A. Jones, A.M. Eroshkin, P. He, R. Williams, S. Bhide, V. Cantagrel, J.G. Gleeson, A.S. Paller, R.E. Schnur, S. Tinschert, J. Zunich, M.R. Hegde, H.H. Freeze, Mutations in the glycosylphosphatidylinositol gene PIGL cause CHIME syndrome, *Am. J. Hum. Genet.* 90 (4) (2012 Apr 6) 685–688.
- [11] Schnur RE1, B.H. Greenbaum, W.R. Heymann, K. Christensen, A.S. Buck, C.S. Reid, Acute lymphoblastic leukemia in a child with the CHIME neuroectodermal dysplasia syndrome, *Am. J. Med. Genet.* 72 (1) (1997 Oct 3) 24–29.
- [12] A. Knight Johnson, G.B. Schaefer, J. Lee, Y. Hu, D. Del Gaudio, Alu-mediated deletion of PIGL in a patient with CHIME syndrome, *Am. J. Med. Genet. A* 173 (5) (2017 May) 1378–1382.
- [13] I. Fujiwara, Y. Murakami, T. Niihori, J. Kanno, A. Hakoda, O. Sakamoto, N. Okamoto, R. Funayama, T. Nagashima, K. Nakayama, T. Kinoshita, S. Kure, Y. Matsubara, Y. Aoki, Mutations in PIGL in a patient with Mabry syndrome, *Am. J. Med. Genet. A* 167A (4) (2015 Apr) 777–785.
- [14] A.T. Pagnamenta, Y. Murakami, J.M. Taylor, C. Anzilotti, M.F. Howard, V. Miller, D.S. Johnson, S. Tadros, S. Mansour, I.K. Temple, R. Firth, E. Rosser, R.E. Harrison, B. Kerr, N. Popitsch, D.D.D. Study, T. Kinoshita, J.C. Taylor, U. Kini, Analysis of exome data for 4293 trios suggests GPI-anchor biogenesis defects are a rare cause of developmental disorders, *Eur. J. Hum. Genet.* 25 (6) (2017 Jun) 669–679.
- [15] D.E. Cole, M.D. Thompson, Neurogenetic aspects of Hyperphosphatasia in Mabry syndrome, *Subcell. Biochem.* 76 (2015) 343–361.
- [16] D. Horn, G. Schottmann, P. Meinecke, Hyperphosphatasia with mental retardation, brachytelephalangy, and a distinct facial gestalt: delineation of a recognizable syndrome, *Eur. J. Med. Genet.* 53 (2) (2010 Mar-Apr) 85–88.
- [17] D. Horn, P. Krawitz, A. Mannhardt, G.C. Korenke, P. Meinecke, Hyperphosphatasia-mental retardation syndrome due to PIGV mutations: expanded clinical spectrum, *Am. J. Med. Genet. A* 155A (8) (2011 Aug) 1917–1922.
- [18] D. Horn, D. Wiczorek, K. Metcalfe, I. Barić, L. Paležac, M. Cuk, D. Petković Ramadža, U. Krüger, S. Demuth, W. Heinritz, T. Linden, J. Koenig, P.N. Robinson, P. Krawitz, Delineation of PIGV mutation spectrum and associated phenotypes in hyperphosphatasia with mental retardation syndrome, *Eur. J. Hum. Genet.* 22 (6) (2014 Jun) 762–767.
- [19] J. Xue, H. Li, Y. Zhang, Z. Yang, Clinical and genetic analysis of two Chinese infants with Mabry syndrome, *Brain Dev.* 38 (9) (2016 Oct) 807–818.
- [20] K. Nakamura, H. Osaka, Y. Murakami, R. Anzai, K. Nishiyama, H. Kodera, M. Nakashima, Y. Tsurusaki, N. Miyake, T. Kinoshita, N. Matsumoto, H. Saitsu, PIGO mutations in intractable epilepsy and severe developmental delay with mild elevation of alkaline phosphatase levels, *Epilepsia* 55 (2) (2014 Feb) e13–7.
- [21] P.M. Krawitz, Y. Murakami, J. Hecht, U. Krüger, S.E. Holder, G.R. Mortier, B. Delle Chiaie, E. De Baere, M.D. Thompson, T. Roscioli, S. Kielbasa, T. Kinoshita, S. Mundlos, P.N. Robinson, D. Horn, Mutations in PIGO, a member of the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation, *Am. J. Hum. Genet.* 91 (1) (2012 Jul 13) 146–151.
- [22] P.M. Krawitz, Y. Murakami, A. Rieß, M. Hietala, U. Krüger, N. Zhu, T. Kinoshita, S. Mundlos, J. Hecht, P.N. Robinson, D. Horn, PGAP2 mutations, affecting the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation syndrome, *Am. J. Hum. Genet.* 4 (92) (2013 Apr) 584–589.
- [23] M.I. Naseer, M. Rasool, M.M. Jan, A.G. Chaudhary, P.N. Pushparaj, A.M. Abuzenadah, M.H. Al-Qahtani, A novel mutation in PGAP2 gene causes developmental delay, intellectual disability, epilepsy and microcephaly in consanguineous Saudi family, *J. Neurol. Sci.* 371 (2016 Dec 15) 121–125.
- [24] M.F. Howard, Y. Murakami, A.T. Pagnamenta, C. Daumer-Haas, B. Fischer, J. Hecht, D.A. Keays, S.J. Knight, U. Kölsch, U. Krüger, S. Leiz, Y. Maeda, D. Mitchell, S. Mundlos, J.A. Phillips III, P.N. Robinson, U. Kini, J.C. Taylor, D. Horn, T. Kinoshita, P.M. Krawitz, Mutations in PGAP3 impair GPI-anchor maturation, causing a subtype of hyperphosphatasia with mental retardation, *Am. J. Hum. Genet.* 94 (2) (2014 Feb 6) 278–287.
- [25] A. Knaus, T. Awaya, I. Helbig, Z. Afawi, M. Pendziwiat, J. Abu-Rachma, M.D. Thompson, D.E. Cole, S. Skinner, F. Annesse, N. Canham, M.R. Schweiger, P.N. Robinson, S. Mundlos, T. Kinoshita, A. Munnich, Y. Murakami, D. Horn, P.M. Krawitz, Rare noncoding mutations extend the mutational spectrum in the PGAP3 subtype of Hyperphosphatasia with mental retardation syndrome, *Hum. Mutat.* 37 (8) (2016 Aug) 737–744.
- [26] T. Chiyonobu, N. Inoue, M. Morimoto, T. Kinoshita, Y. Murakami, Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in PIGW is associated with west syndrome and hyperphosphatasia with mental retardation syndrome, *J. Med. Genet.* 51 (3) (2014 Mar) 203–207.
- [27] B. Ilkovič, A.T. Pagnamenta, G.L. O'Grady, T. Kinoshita, M.F. Howard, M. Lek, B. Thomas, A. Turner, J. Christodoulou, D. Silience, S.J. Knight, N. Popitsch, D.A. Keays, C. Anzilotti, A. Gorieli, L.B. Waddell, F. Filot, K.N. North, N. Kanzawa, D.G. Macarthur, J.C. Taylor, U. Kini, Y. Murakami, N.F. Clarke, Mutations in PIGY: expanding the phenotype of inherited glycosylphosphatidylinositol deficiencies, *Hum. Mol. Genet.* 24 (21) (2015 Nov 1) 6146–6159.
- [28] P. Rabe, F. Haverkamp, D. Emons, R. Roszkamp, K. Zerres, E. Passarge, Syndrome of developmental retardation, facial and skeletal anomalies, and hyperphosphatasia in two sisters: nosology and genetics of the coffin-Siris syndrome, *Am. J. Med. Genet.* 41 (3) (1991 Dec 1) 350–354.
- [29] Y. Murakami, N. Kanzawa, K. Saito, P.M. Krawitz, S. Mundlos, P.N. Robinson, A. Karadimitris, Y. Maeda, T. Kinoshita, Mechanism for release of alkaline phosphatase caused by glycosylphosphatidylinositol deficiency in patients with hyperphosphatasia mental retardation syndrome, *J. Biol. Chem.* 287 (9) (2012 Feb 24) 6318–6325.
- [30] B.G. Ng, H.H. Freeze, Human genetic disorders involving glycosylphosphatidylinositol (GPI) anchors and glycosphingolipids (GSL), *J. Inher. Metab. Dis.* 38 (1) (2015 Jan) 171–178.
- [31] M.D. Thompson, A. Killoran, M.E. Percy, M. Nezarati, D.E. Cole, P.A. Hwang, Hyperphosphatasia with neurologic deficit: a pyridoxine-responsive seizure disorder? *Pediatr. Neurol.* 34 (4) (2006 Apr) 303–307.
- [32] I. Kuki, Y. Takahashi, S. Okazaki, H. Kawawaki, E. Ehara, N. Inoue, T. Kinoshita, Y. Murakami, Vitamin B6-responsive epilepsy due to inherited GPI deficiency, *Neurology* 81 (16) (2013 Oct 15) 1467–1469.